Aduro is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.
January 30, 2019 Aduro Biotech Announces Strategic Reset
Events & Presentations
November 09, 2018Aduro's 1st Forum on STING at SITC 2018
Data provided by Nasdaq. Minimum 15 minutes delayed.